Magnetic core-shell nanoparticles for drug delivery by nebulization

Journal of Nanobiotechnology

Volumn 11, Issue 1, 2013, Pages

  Verma, Navin Kumar ^a   Crosbie Staunton, Kieran ^a   Satti, Amro ^a   Gallagher, Shane ^a   Ryan, Katie B ^b   Doody, Timothy ^b   McAtamney, Colm ^a   MacLoughlin, Ronan ^c   Galvin, Paul ^d   Burke, Conor S ^e   Volkov, Yuri ^a   Gun'ko, Yurii K ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c Aerogen Ltd   (Ireland)

^d UNIVERSITY COLLEGE CORK   (Ireland)

^e DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Drug delivery; Magnetite nanoparticles; Nanomedicine; Nebulization; Quercetin

Indexed keywords

A549 CELLS; AEROSOL FORMATION; ANTICANCER DRUG; AVERAGE PARTICLE SIZE; BIOLOGICAL TESTS; CELL-BASED; CORE-SHELL; CORE-SHELL NANOPARTICLES; DRUG DELIVERY VEHICLES; GLUTATHIONES; HUMAN LUNG; HUMAN LUNG CARCINOMA CELLS; IMPEDANCE SENSING; IN-VIVO; LUNG CANCER; LUNG CANCER CELLS; MAGNETIC NANOPARTICLES; NANOCARRIERS; NEBULIZATION; POLY(LACTIC-CO-GLYCOLIC ACID); POLYMERIC SHELL; POST TREATMENT; QUERCETIN; SURFACE COATINGS; TARGETED DELIVERY;

AEROSOLS; BIOLOGICAL ORGANS; CELL CULTURE; DISEASES; DRUG DELIVERY; ELECTRON MICROSCOPY; FATTY ACIDS; FLAVONOIDS; MAGNETIC CORES; MAGNETITE NANOPARTICLES; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; PHENOLS; POLYMERS; RESPIRATORY SYSTEM; SYNTHESIS (CHEMICAL);

COPOLYMERS;

GLUTATHIONE; INTERLEUKIN 6; MAGNETITE NANOPARTICLE; POLYGLACTIN; QUERCETIN;

AEROSOL; ARTICLE; AUTOMATION; BIOCOMPATIBILITY; CANCER CELL; CANCER CELL CULTURE; CELL VIABILITY; CHEMICAL ANALYSIS; DRUG DELIVERY SYSTEM; DRUG TARGETING; ELECTRON MICROSCOPY; EPITHELIUM CELL; HUMAN; HUMAN CELL; HYDRODYNAMICS; IN VIVO STUDY; LIGHT SCATTERING; LUNG CANCER; NEBULIZATION; NONHUMAN; PARTICLE SIZE; SYNTHESIS;

AEROSOLS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; GLUTATHIONE; HUMANS; INTERLEUKIN-6; LACTIC ACID; MAGNETICS; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS; QUERCETIN;

MUS;

EID: 84872512129     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-11-1     Document Type: Article

References (70)

1. Shao H, Min C, Issadore D, Liong M, Yoon TJ, Weissleder R, Lee H. Magnetic nanoparticles and microNMR for diagnostic applications. Theranostics 2012, 2:55-65. 10.7150/thno.3465, 3263516, 22272219.
2. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26:3995-4021. 10.1016/j.biomaterials.2004.10.012, 15626447.
3. Xie J, Huang J, Li X, Sun S, Chen X. Iron oxide nanoparticle platform for biomedical applications. Curr Med Chem 2009, 16:1278-1294. 10.2174/092986709787846604, 19355885.
4. Xie J, Liu G, Eden HS, Ai H, Chen X. Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc Chem Res 2011, 44:883-892. 10.1021/ar200044b, 3166427, 21548618.
5. Corr S, Gun'ko YK, Douvalis A, Venkatesan M, Gunning R, Nellist P. From nanocrystals to nanorods: new iron oxide-silica nanocomposites from metallorganic precursors. J Phys Chem C 2008, 112:1008-1018.
6. Nowostawska M, Corr SA, Byrne SJ, Conroy J, Volkov Y, Gun'ko YK. Porphyrin-magnetite nanoconjugates for biological imaging. J Nanobiotechnol 2011, 9:13.
7. Tiefenauer LX. Magnetic nanoparticles as contrast agents for medical diagnosis. Nanotechnology in Biology and Medicine. Methods, Devices, and Applications. Chapter 29 2007, 1-20. CRC Press, Vo-Dinh T.
8. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 2001, 11:2319-2331. 10.1007/s003300100908, 11702180.
9. Akbarzadeh A, Samiei M, Davaran S. Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. Nanoscale Res Lett 2012, 7:144. 10.1186/1556-276X-7-144, 3312841, 22348683.
10. Byrne SJ, Corr SA, Gun'ko YK, Kelly JM, Brougham DF, Ghosh S. Magnetic nanoparticle assemblies on denatured DNA show unusual magnetic relaxivity and potential applications for MRI. Chem Comm 2004, 22:2560-2561.
11. Corr SA, Byrne SJ, Tekoriute R, Meledandri CJ, Brougham DF, Lynch M, Kerskens C, O'Dwyer L, Gun'ko YK. Linear assemblies of magnetic nanoparticles as MRI contrast agents. J Amer Chem Soc 2008, 130:4214-4215.
12. Akbarzadeh A, Mikaeili H, Zarghami N, Mohammad R, Barkhordari A, Davaran S. Preparation and in vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymers. Int J Nanomed 2012, 7:511-526.
13. Douziech-Eyrolles L, Marchais H, Hervé K, Munnier E, Soucé M, Linassier C, Dubois P, Chourpa I. Nanovectors for anticancer agents based on superparamagnetic iron oxide nanoparticles. Int J Nanomedicine 2007, 2:541-550. 2676819, 18203422.
14. Corot C, Robert P, Idée JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006, 58:1471-1504. 10.1016/j.addr.2006.09.013, 17116343.
15. Huh YM, Jun YW, Song HT, Kim S, Choi JS, Lee JH, Yoon S, Kim KS, Shin JS, Suh JS, Cheon J. In vivo magnetic resonance detection of cancer by using magnetic nanocrystals. J Am Chem Soc 2005, 127:12387-12391. 10.1021/ja052337c, 16131220.
16. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 2005, 23:1418-1423. 10.1038/nbt1159, 16244656.
17. Corr S, Gun'ko YK. Multifunctional magnetic-fluorescent nanocomposites for biomedical applications. Nanoscale Res Lett 2008, 3:87-104.
18. McCarthy JE, Prina-Mello A, Rakovich T, Volkov Y, Gun'ko YK. Fabrication and characterization of multimodal magnetic - fluorescent polystyrene nanowires as selective cell imaging probes. J Mater Chem 2011, 21:14219-14225.
19. Davies GL, Corr SA, Meledandri CJ, Briode L, Brougham DF, Gun'ko YK. NMR relaxation of water in nanostructures: analysis of ferromagnetic cobalt-ferrite polyelectrolyte nanocomposites. Chemphyschem 2011, 12:772-776. 10.1002/cphc.201000853, 21387521.
20. Gallagher JJ, Tekoriute R, O'Reilly JA, Kerskens C, Gun'ko YK, Lynch M. Bimodal magnetic-fluorescent nanostructures for biomedical applications. J Mater Chem 2009, 19:4081-4084.
21. Corr SA, Gun'ko YK, Tekoriute R, Meledandri CJ, Brougham DF. Poly(sodium-4-styrene)sulfonate - iron-oxide nanocomposite dispersions with controlled magnetic resonance properties. J Phys Chem C 2008, 112:13324-13327.
22. Corr SA, O'Byrne A, Gun'ko YK, Ghosh S, Brougham DF, Mitchell S, Volkov Y, Prina-Mello A. Magnetic-fluorescent nanocomposites for biomedical multitasking. Chem Comm 2006, 43:4474-4476.
23. O'Riordan TG. Aerosol delivery devices and obstructive airway disease. Expert Rev Med Devices 2005, 2:197-203. 10.1586/17434440.2.2.197, 16293056.
24. Hagerman JK, Hancock KE, Klepser ME. Aerosolised antibiotics: a critical appraisal of their use. Expert Opin Drug Deliv 2006, 3:71-86. 10.1517/17425247.3.1.71, 16370941.
25. Rao RD, Markovic SN, Anderson PM. Aerosol therapy for malignancy involving the lungs. Curr Cancer Drug Targets 2003, 3:239-250. 10.2174/1568009033481895, 12871055.
26. Zarogoulidis P, Chatzaki E, Porpodis K, Domvri K, Hohenforst-Schmidt W, Goldberg EP, Karamanos N, Zarogoulidis K. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int J Nanomedicine 2012, 7:1551-1572. 10.2217/nnm.12.42, 3356182, 22619512.
27. Dames P, Gleich B, Flemmer A, Hajek K, Seidl N, Wiekhorst F, Eberbeck D, Bittmann I, Bergemann C, Weyh T, Trahms L, Rosenecker J, Rudolph C. Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol 2007, 2:495-499. 10.1038/nnano.2007.217, 18654347.
28. Gagnadoux F, Hureaux J, Vecellio L, Urban T, Le Pape A, Valo I, Montharu J, Leblond V, Boisdron-Celle M, Lerondel S, Majoral C, Diot P, Racineux JL, Lemarie E. Aerosolized chemotherapy. J Aerosol Med Pulm Drug Deliv 2008, 21:61-70. 10.1089/jamp.2007.0656, 18518832.
29. Roa WH, Azarmi S, Al-Hallak MH, Finlay WH, Magliocco AM, Löbenberg R. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Control Release 2011, 150:49-55. 10.1016/j.jconrel.2010.10.035, 21059378.
30. Otterson GA, Villalona-Calero MA, Sharma S, Kris MG, Imondi A, Gerber M, White DA, Ratain MJ, Schiller JH, Sandler A, Kraut M, Mani S, Murren JR. Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res 2007, 13:1246-1252. 10.1158/1078-0432.CCR-06-1096, 17317836.
31. Otterson GA, Villalona-Calero MA, Hicks W, Pan X, Ellerton JA, Gettinger SN, Murren JR. Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin Cancer Res 2010, 16:2466-2473. 10.1158/1078-0432.CCR-09-3015, 20371682.
32. Zheng SY, Li Y, Jiang D, Zhao J, Ge JF. Anticancer effect and apoptosis induction by quercetin in the human lung cancer cell line A-549. Mol Med Report 2012, 5:822-826.
33. Di Carlo G, Mascolo N, Izzo A, Capasso F. Flavonoids: old and new aspects of a class of natural therapeutic drugs. Life Sci 1999, 65:337-353. 10.1016/S0024-3205(99)00120-4, 10421421.
34. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003, 52:981-986. 10.1093/jac/dkg477, 14613962.
35. Park J, Fong PM, Lu J, Russell KS, Booth KJ, Saltzman WM, Fahmy TM. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine (Lond) 2009, 5:410-418.
36. Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaría J. Magnetic nanoparticles for drug delivery. Nano Today 2007, 2:22-32.
37. Neuberger T, Schopf B, Hofmann H, Hofmann M, Von Rechenberg B. Superpara-magnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system. J Magn Magn Mater 2005, 293:483-496.
38. Grassi-Schultheiss PP, Heller F, Dobson J. Analysis of magnetic material in the human heart, spleen and liver. Biometals 1997, 10:351-355. 10.1023/A:1018340920329, 9353885.
39. Alexiou C, Tietze R, Schreiber E, Jurgons R, Richter H, Trahms L, Rahn H, Odenbach S, Lyer S. Cancer therapy with drug loaded magnetic nanoparticles-magnetic drug targeting. J Magn Magn Mater 2011, 323:1404-1407.
40. Tietze R, Lyer S, Dürr S, Alexiou C. Nanoparticles for cancer therapy using magnetic forces. Nanomedicine (Lond) 2012, 7:447-457.
41. McCarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev 2008, 60:1241-1251. 10.1016/j.addr.2008.03.014, 2583936, 18508157.
42. Laurent S, Forge D, Port M, Roch A, Robic C, Elst LV, Muller RN. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev 2008, 108:2064-2110. 10.1021/cr068445e, 18543879.
43. Singh N, Jenkins GJS, Asadi R, Doak SH. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev 2010, 1:5358.
44. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 2007, 120:18-26. 10.1016/j.jconrel.2007.03.012, 17509712.
45. Lin W, Huang YW, Zhou XD, Ma Y. In vitro toxicity of silica nanoparticles in human lung cancer cells. Toxicol Appl Pharmacol 2006, 217:252-259. 10.1016/j.taap.2006.10.004, 17112558.
46. Mohamed BM, Verma NK, Prina-Mello A, Williams Y, Davies AM, Bakos G, Tormey L, Edwards C, Hanrahan J, Salvati A, Lynch I, Dawson K, Kelleher D, Volkov Y. Activation of stress-related signalling pathway in human cells upon SiO2 nanoparticles exposure as an early indicator of cytotoxicity. J Nanobiotechnol 2011, 9:29.
47. Verma NK, Moore E, Blau W, Volkov Y, Ramesh Babu P. Cytotoxicity evaluation of nanoclays in human epithelial cell line A549 using high content screening and real-time impedance analysis. J Nanopart Res 2012, 14:1137.
48. Ekstrand-Hammarström B, Akfur CM, Andersson PO, Lejon C, Österlund L, Bucht A. Human primary bronchial epithelial cells respond differently to titanium dioxide nanoparticles than the lung epithelial cell lines A549 and BEAS-2B. Nanotoxicol 2012, 6:623-634.
49. Solly K, Wang X, Xu X, Strulovici B, Zheng W. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev Technol 2004, 2:363-372. 10.1089/adt.2004.2.363, 15357917.
50. Wegener J, Keese CR, Giaever I. Electric cell-substrate impedance sensing (ECIS) as a noninvasive means to monitor the kinetics of cell spreading to artificial surfaces. Exp Cell Res 2000, 259:158-166. 10.1006/excr.2000.4919, 10942588.
51. Kelly GS. Quercetin. Monograph. Altern Med Rev 2011, 16:172-194.
52. Graefe EU, Derendorf H, Veit M. Pharmacokinetics and bioavailability of the flavonol quercetin in humans. Int J Clin Pharmacol Ther 1999, 37:219-233.
53. Anderson ME. Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact 1998, 111-112:1-14.
54. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011, 1813:878-888. 10.1016/j.bbamcr.2011.01.034, 21296109.
55. Park EJ, Kim H, Kim Y, Yi J, Choi K, Park K. Inflammatory responses may be induced by a single intratracheal instillation of iron nanoparticles in mice. Toxiciology 2010, 275:65-71.
56. Hara K, Tsujimoto H, Tsukada Y, Huang CC, Kawashima Y, Tsutsumi M. Histological examination of PLGA nanospheres for intratracheal drug administration. Int J Pharm 2008, 356:267-273. 10.1016/j.ijpharm.2007.12.041, 18276091.
57. Hasenpusch G, Geiger J, Wagner K, Mykhaylyk O, Wiekhorst F, Trahms L, Heidsieck A, Gleich B, Bergemann C, Aneja MK, Rudolph C. Magnetized aerosols comprising superparamagnetic iron oxide nanoparticles improve targeted drug and gene delivery to the lung. Pharm Res 2012, 29:1308-1318. 10.1007/s11095-012-0682-z, 22271050.
58. Bennett WD. Controlled inhalation of aerosolised therapeutics. Expert Opin Drug Deliv 2005, 2:763-767. 10.1517/17425247.2.4.763, 16296800.
59. Brand P, Beckmann H, Maas Enriquez M, Meyer T, Müllinger B, Sommerer K, Weber N, Weuthen T, Scheuch G. Peripheral deposition of α1-protease inhibitor using commercial inhalation devices. Eur Respir J 2003, 22:263-267. 10.1183/09031936.03.00096802, 12952258.
60. Sharma S, White D, Imondy AR, Placke ME, Vail DM, Kris MG. Development of inhalational agents for oncologic use. J Clin Oncol 2001, 19:1839-1847.
61. Dhand R, Sohal H. Pulmonary Drug Delivery System for inhalation therapy in mechanically ventilated patients. Expert Rev Med Devices 2008, 5:9-18. 10.1586/17434440.5.1.9, 18095891.
62. MacLoughlin RJ, Higgins BD, Laffey JG, O'Brien T. Optimized aerosol delivery to a mechanically ventilated rodent. J Aerosol Med Pulm Drug Deliv 2009, 22:323-332. 10.1089/jamp.2008.0717, 19415985.
63. Mohamed BM, Verma NK, Davies AM, McGowan A, Crosbie-Staunton K, Prina-Mello A, Kelleher D, Botting CH, Causey CP, Thompson PR, Pruijn GJ, Kisin ER, Tkach AV, Shvedova AA, Volkov Y. Citrullination of proteins: a common post-translational modification pathway induced by different nanoparticles in vitro and in vivo. Nanomedicine (Lond) 2012, 7:1181-1195.
64. Jan E, Byrne SJ, Cuddihy M, Davies AM, Volkov Y, Gun'ko YK, Kotov NA. High-content screening as a universal tool for fingerprinting of cytotoxicity of nanoparticles. ACS Nano 2008, 2:928-938. 10.1021/nn7004393, 19206490.
65. Long A, Volkov Y. High content analysis approach for targeted gene silencing and probing nanoscale cell responses. Eur Pharm Rev 2009, 1:22-30.
66. Byrne F, Prina-Mello A, Whelan A, Mohamed BM, Davies A, Gun'ko Y, Coey JMD, Volkov Y. High content analysis of the biocompatibility of nickel nanowires. J Magn Magn Mater 2009, 321:1341-1345.
67. Movia D, Prina-Mello A, Volkov Y, Giordani S. Determination of spiropyran cytotoxicity by high content screening and analysis for safe application in bionanosensing. Chem Res Toxicol 2010, 23:1459-1466. 10.1021/tx100123g, 20809582.
68. Verma NK, Conroy J, Lyons PE, Coleman J, O'Sullivan MP, Kornfeld H, Kelleher D, Volkov Y. Autophagy induction by silver nanowires: A new aspect in the biocompatibility assessment of nanocomposite thin films. Toxicol Appl Pharmacol 2012, 264:451-461. 10.1016/j.taap.2012.08.023, 22959926.
69. Lysaght J, Verma NK, Maginn EN, Ryan JM, Campiani G, Zisterer DM, Williams DC, Browne PV, Lawler MP, McElligott AM. The microtubule targeting agent PBOX-15 inhibits integrin-mediated cell adhesion and induces apoptosis in acute lymphoblastic leukaemia cells. Int J Oncol 2013, 42:239-246.
70. Hassett P, Curley GF, Contreras M, Masterson C, Higgins BD, O'Brien T, Devaney J, O'Toole D, Laffey JG. Overexpression of pulmonary extracellular superoxide dismutase attenuates endotoxin-induced acute lung injury. Intensive Care Med 2011, 37:1680-1687. 10.1007/s00134-011-2309-y, 21755396.